Navigation Links
Biopure Announces 2007 Third Quarter Financial Results
Date:8/23/2007

for each new case. To date, the FDA has approved all requests for compassionate use and granted 20 single-patient INDs to Biopure for the treatment of individual patients with life-threatening anemia when red blood cell transfusion was not an option. Thirteen patients have been treated for acute anemia resulting from blood loss or chemotherapy treatment.

U.S. Navy Program.

Following recommendations by the FDA Blood Products Advisory Committee (BPAC) meeting held in December 2006, the Navy Medical Research Center (NMRC) with support from Biopure submitted last month a new RESUS (Restore Effective Survival in Shock) study protocol for a Phase 2 out-of-hospital trauma study of Biopure's oxygen therapeutic Hemopure. In a recent letter to the NMRC, the FDA has kept the revised study protocol for RESUS on clinical hold. Biopure is still evaluating the letter and anticipates having further discussions with the NMRC and the FDA in the near future on this subject.

Ongoing Trials

Based on pre-clinical studies, the company believes that Hemopure can help improve tissue oxygenation, organ function and/or wound healing by transporting oxygen through constricted or partially blocked arteries and improving collateral circulation to oxygen-deprived tissues. A 60-patient clinical trial in patients undergoing multi-vessel coronary artery bypass graft (CABG) surgery continues to enroll patients in South Africa, Greece and the U.K. and has enrolled 33 patients. The objective of this trial is to assess the safety and feasibility of Hemopure in reducing heart damage, as measured by cardiac enzyme elevation, and enhancing tissue preservation during CABG surgery. In the Netherlands an 8 patient phase 2 safety and feasibility study in patients with multi-vessel coronary artery disease who are undergoing percutaneous coronary intervention (PCI), also continues to enroll patients. This trial is testing the hypothesis that Hemopure may improve oxygenation and heart func
'/>"/>

SOURCE Biopure Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015  Rigel Pharmaceuticals, Inc. (Nasdaq: ... quarter and six months ended June 30, 2015. ... ITP are progressing and we continue to expect results ... , president and chief executive officer of Rigel. "We ... clinical programs, including evaluating fostamatinib for new treatment indications, ...
(Date:8/4/2015)... 2015  Dr. Keesha Ewers of ... approval of flibanserin, or what is being touted ... of decreased female sexual desire back several decades. ... and addressing libido as a singular symptom with ... Photo - ...
(Date:8/4/2015)...  MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology ... cancer, announced today that Daniel P. Gold , Ph.D., ... Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015 at ... in New York . A live webcast ... A replay will be available approximately one hour after the ...
Breaking Medicine Technology:Rigel Announces Second Quarter 2015 Financial Results 2Rigel Announces Second Quarter 2015 Financial Results 3Rigel Announces Second Quarter 2015 Financial Results 4Rigel Announces Second Quarter 2015 Financial Results 5Rigel Announces Second Quarter 2015 Financial Results 6Potential FDA Approval of "Pink Viagra" Sends Wrong Message 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 3Potential FDA Approval of "Pink Viagra" Sends Wrong Message 4Potential FDA Approval of "Pink Viagra" Sends Wrong Message 5MEI Pharma to Present at Wedbush PacGrow Healthcare Conference 2
... FORT MYERS, Fla., May 11, 2011 Radiation ... radiation therapy centers, today announced financial results for the first ... the first quarter of 2011 were $156.5 million, an increase ... same quarter of 2010. The increase in revenue was principally ...
... 2011 Doctors in Germany are among the first ... with the REVIVE™ SE, a new self-expanding blood clot ... and restore blood flow to the brain in patients ... Inc., a global neuroscience and neurovascular company, received Conformite ...
Cached Medicine Technology:Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 2Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 3Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 4Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 5Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 6Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 7Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 8Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 9Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 10Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 11Doctors in Germany Among First to Use New Self-Expanding Clot Removal Device for Ischemic Stroke 2Doctors in Germany Among First to Use New Self-Expanding Clot Removal Device for Ischemic Stroke 3
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... Many men ... on the subject, Renew Man™ is standing up as a voice of authority for ... of the healthy aging industry with special experience and expertise in the safe and ...
(Date:8/4/2015)... ... ... 24/7 Care At Home , a provider of comprehensive home health ... the U.S. Department of Veteran’s Affairs (VA) has awarded its agency a rating of ... the path to meeting the aspirational goals the VA promotes each year. , ...
(Date:8/4/2015)... Ohio (PRWEB) , ... August 04, 2015 , ... ... have up-to-date immunizations, especially those entering kindergarten. All required immunizations are covered for ... rules, which means that children who aren’t caught up with their immunizations may ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... firms and government entities, today announced that John Munro, a 15-year veteran of ... President of Managed Services Operations. , “I am thrilled to join Discovia at ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... announced that Bruce McCalley joins its executive leadership team as Senior Vice President ... success at technology companies and expanding global markets with a special emphasis on ...
Breaking Medicine News(10 mins):Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 3Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3
... conducted by the anthropologists, from the University of Connecticut, University ... , ,They said that Neanderthals were very good in hunting ... modern humans. ,But the early modern humans ... due to the competition they received from the early modern ...
... by scientists belonging to the Northwestern University targeted at ... //The gene therapy, described in the January online issue ... Bohn and her laboratory group at Northwestern University Feinberg ... Medical Research Council Professor and director of the neurobiology ...
... on the rise and is rapidly becoming the number one cancer ... seriousness of the situation is apparent after going through recent data ... ,The rise is being documented mainly in the metros, but it ... unnoticed. It is reported that one in 22 women in India ...
... more than a couple of seconds to decide whether the ... findings. The decision is often taken in less than a ... impossible to really see anything in less than 500 milliseconds,’ ... has published the research in the journal Behavior and Information ...
... improvements made in diagnoses and treatment of the fatal ... a cure rate of 90%, according to researchers belonging ... ,The progressive improvement in the cure rate since ... reflects in large part the more effective use of ...
... to medical science, doctors under the leadership of Dr Hasan ... would perform surgery on patients while they// are in a ... out from their bodies while the surgery is being performed ... is complete. ,The return of blood would be ...
Cached Medicine News:Health News:Acute Lymphoblastic Leukemia May Attain a 90% Cure Rate 2
... Sensor is the first sensor designed specifically ... sensor is the first and only sensor ... and children. Cyanotic infants and children ... and accurate pulse oximetry, and Masimo's research ...
ELISA kit for Varicella-zoster IgG detection....
... Virus (VZV) IgG Enzyme-Linked Immunosorbent Assay (ELISA) ... determination of IgG antibody to VZV in ... be used for the determination of immune ... be used to demonstrate seroconversion or a ...
Inquire...
Medicine Products: